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Diffuse large B-cell lymphoma (DLBCL) is the most common canine aggressive B-cell 
lymphoma worldwide, and new recent molecular approaches have shown that DLBCL 
constitutes a heterogeneous tumor that cannot be unraveled by morphology and 
immunophenotype. DLBCL behaves aggressively, typically progressing over a short 
period of time, and the therapy response may be difficult to be predicted. Recently, 
the rate of bone marrow infiltration by flow cytometry has been demonstrated to be 
prognostic, but more sensible markers are needed. As the clinical behavior is different, 
there is vast clinical and basic research devoted to identifying prognostically or biolog-
ically distinct DLBCL subgroups. Transcriptomic analysis by gene expression profile, 
copy number variations by array comparative genomic hybridization and epigenetic 
perturbations have tentatively described this heterogeneity. Molecular subgroups using 
oncogenic pathways and target genes have also been correlated to different outcome 
in a small number of cases. The objectives of this review are to summarize the current 
knowledge on the biology, clinical, and pathological characteristics of canine DLBCL. To 
date, DLBCL probably is the most investigated tumor in veterinary medicine, and its rel-
evance as spontaneous model for human DLBCL has been confirmed by these studies. 
In future, these discoveries will ultimately lead to a better understanding of the underlying 
disease mechanisms, possibly translating into more effective therapeutic strategies.
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inTRODUCTiOn
Lymphoma is a generic term that generally groups a heterogeneous disease, encompassing a number 
of subtypes of varying malignancy that occur as the result of neoplastic transformation of B and T 
lymphocytes at different stages of development. While diagnosing lymphoma as a general entity can 
be relatively straightforward via standard cytology, describing the different subtypes and anticipating 
their biologic behavior is still challenging (1). In addition to the morphological characteristics of 
neoplastic lymphocytes, the identification of the cell lineage and molecular features currently aid in 
the accurate classification of lymphoma. Routinely, cytology may be integrated by flow cytometry 
(FC). The major principles of this technique are the simultaneous measurement of a very large num-
ber of cells and the recording of multiple parameters for individual cells such as size, complexity, and 
fluorescence features. In contrast with other immunophenotyping methods, FC is easy to perform 
2Aresu DLBCL More Than a Diagnosis
Frontiers in Veterinary Science | www.frontiersin.org August 2016 | Volume 3 | Article 77
and can produce results in a short time. Furthermore, FC has 
several applications such as lineage assessment, evaluation of 
degree of maturation, antigen quantitation/aberration, cell pro-
liferation activity, and tumor staging (2–6). However, the limited 
number of antibodies available in veterinary medicine compared 
with human medicine, and the risk of misdiagnosing different 
subtypes of lymphoma, such as indolent lymphomas, still repre-
sent the two major disadvantages of the combined use of cytology 
and FC (7). Another disadvantage of FC is represented by the 
need to obtain a sufficient number of live cells for the analysis.
Conventional histopathology is mainly associated to immu-
nohistochemistry (IHC) providing valuable architectural and 
immunophenotypic information, respectively. Nowadays, the 
histopathologic classification proposed by the World Health 
Organization is recommended. An algorithm to approach the 
morphological diagnosis has been recently provided, and con-
siders the following: (1) neoplastic growth pattern, (2) nuclear 
size, (3) nuclear morphology, (4) number of mitoses per high-
power field, and (5) immunophenotype (8). Recently, a group 
of international veterinary pathologists achieved agreement of 
80% in the application of the WHO classification criteria for 
the diagnosis of canine lymphoma based on histology and IHC, 
also highlighting the need to obtain the whole lymph node for 
the diagnosis, thereby discouraging the use of tru-cut biopsy. In 
fact, fragmented nodal tissues may be more difficult to interpret 
than intact organs (8). However, the invasive procedure of lym-
phadenectomy and its associated costs are reported as limits by 
practitioners.
In 2003, PCR for antigen receptor rearrangement (PARR) 
has been developed for dogs, and promising results have been 
described in the last ten years in terms of improving diagnosis 
and detecting minimal residual disease (9). The PARR technique 
refers to the concept that lymphoma is a clonal expansion of lym-
phocytes with specific DNA regions that are unique in both length 
and sequence in the neoplastic lymphocytes. An advantage of 
PARR is that it can be performed on cells obtained via aspiration, 
fluid samples, small tissue samples, and cell smears potentially 
establishing the presence of a malignancy and discriminating 
phenotype (9, 10). The limits of detection of neoplasia with the 
PCR assay depend on the sampled tissue, but the general assay is 
about one neoplastic cell in 1,000 non-neoplastic cells. Despite FC 
tends to show a higher sensitivity compared with PARR, whenever 
fresh samples are not available, PARR becomes fundamental for 
determination of immunophenotype as shown by Thalheim et al. 
Only recently, the use of molecular analysis to evaluate minimal 
residual disease in post-therapy samples has been considered to 
determine prognosis or opting for rescue therapy in dogs with 
B-cell lymphoma. However, the clinical significance of this type 
of testing is still controversial since consensus primers of IgH have 
a low sensitive for detection of minimal residual disease (11, 12). 
In one study, canine-specific primers have been used for residual 
disease detection of immunoglobulin gene rearrangements (13). 
Despite the method used is innovative in veterinary medicine, 
this is time-consuming and a quite expensive process where the 
original tumor clones are amplified using consensus primers, and 
the PCR product is then sequenced. Unfortunately, this approach 
is still routinely unavailable.
Even though the morphological diagnosis criteria, molecular 
tests, and FC performance in canine lymphoma have significantly 
improved in the recent years, treatment strategies have not 
accordingly evolved, and no therapeutic guidelines have been 
stratified based on the WHO histotype classification. Diffuse 
Large B-cell lymphoma (DLBCL) is the most frequent lymphoma 
histotype, and recent investigations have contributed to improve 
therapeutic approaches and to determine the genetic of this 
tumor, starting from the consideration that dogs with DLBCL 
have markedly different clinical courses and treatment responses. 
The main goal of this article is to review the most recent advances 
in clinical, pathologic, and molecular characteristics in dogs 
affected by DLBCL.
Clinical and Prognostic Features of DLBCL
Clinically, dogs affected by DLBLC show a moderate to severe 
enlargement of peripheral lymph nodes (1). Histologically, 
DLBCL is characterized by a diffuse proliferation of large neo-
plastic lymphoid cells with nuclear size more than twice the size 
of red blood cells. The centroblast variant is the most frequent one 
and is characterized by a diffuse proliferation of large, not cleaved, 
lymphoid cells resembling the proliferating cells of the germinal 
center (GC) with oval to round vesicular nuclei with fine chro-
matin, and scanty amphophilic to basophilic cytoplasm. Nucleoli 
are always visible and multiple. The immunoblast variant in dogs 
is less frequent and considered clinically more aggressive. By 
IHC, DLBCLs express CD79, CD20, and the nuclear transcrip-
tion factor PAX5 (14). Dogs with DLBCL have variable clinical 
course, response to treatment, and prognosis, which may depend 
on many clinicopathological and morphological parameters. 
Furthermore, a proportion of canine DLBCL seems to occur from 
evolution of follicular lymphomas and marginal lymphomas 
through a mechanism described as transformation. In veterinary 
medicine, this transformation has been characterized only by 
histology, but it may reflect more complicated biologic events 
leading to new mutations in coding regions (15).
A value of 3% infiltrating neoplastic cells in bone marrow (BM) 
has been defined as the most useful and feasible cut-off in dogs with 
DLBCL to discriminate BM infiltration. Also, lymphoma survival 
and time to progression were significantly associated to this value 
(16). Previously, Valli et al. have demonstrated that the number 
of mitosis is associated with clinical follow-up of dogs affected by 
DLBCL. Interestingly, the median survival of dogs with less than 
20 mitoses per 400 field was 188 days; in contrast, the median 
survival of dogs with a number higher than 20 mitoses per 400 
field was 31 days (14). Unfortunately, the dogs received multiple 
treatments and disease stages were not consistently reported.
Molecular Pathogenesis of DLBCL
In 2013, Frantz et al. were the first authors to approach canine 
lymphoma by gene expression profile (GEP) analysis. Using DNA 
microarrays, 35 lymphomas representing the most common his-
tologic subtypes were investigated, comprising DLBCL (17, 18). 
DNA microarray technology allows the screening of thousands 
of expressed genes in a single experiment, and the advantages 
of using such technique in canine lymphoma research are twice. 
First, transcriptome analysis of neoplastic lymphocytes compared 
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with normal lymphocyte population may help to define the 
pathogenetic mechanisms underlying the tumor development. 
This was well demonstrated in a recent elegant paper published 
on canine DLBCL, where the dataset of 23 tumor samples and 
10 control lymph nodes clustered in 2 well-separated clusters 
(19). A total of 3286 genes were differently expressed, and most 
of them were downregulated in DLBCL compared with normal 
lymphocytes (n = 2360). The second advantage of transcriptome 
analysis is the identification of specific signatures that are useful 
to molecularly classify the tumor that would look similar based 
on the morphological aspects. This type of approach was reported 
approximately 20 years ago in human medicine (20). A ground-
breaking discovery permitted to separate human DLBCL into two 
distinct subtypes based on their peculiar specific gene expression 
signatures. One subtype was characterized by the expression of 
genes typical of GC B cells, the other by the expression of genes 
that were upregulated in activated B cells (ABC). Patients with 
GC-DLBCLs and ABC-DLBCLs have significantly different 
survival rates following chemotherapy. Whereas patients with 
GCB DLBCL respond favorably to rituximab and chemotherapy, 
more than 50% of ABC DLBCL patients will succumb to their 
disease (20). This pioneering study leads to the current proposal 
that GC-DLBCLs and ABC-DLBCLs represent two distinct 
biological disease entities. Similarly, in 2014, Richards et  al. 
presented an elegant study where they applied DNA microarray 
technology in a group of dogs affected by B-cell lymphomas, 32 
of which were diagnosed as DLBCL. Genes that distinguish ABC 
and GCB human DLBCL separate canine B-cell lymphomas 
into two groups that showed statistically different survival times 
(21). Finally, a list of the most significant genes were studied and 
were found to be involved in the same pathways and processes of 
human DLBCL. NF-κB signaling and B-cell receptor signaling 
were the most relevant ones.
Genetic Landscape of DLBCL
Lymphoma and cancer, in general, are diseases characterized by 
chromosomal modifications compared with the germ line DNA, 
and genes that display abnormal expression in aberrant chromo-
somal regions are likely to be key players in tumor initiation and 
progression. The first reports to detect chromosomal changes in 
canine lymphomas were based on conventional cytogenetic (22). 
In recent years, the technology of the array comparative genomic 
hybridization (aCGH) has been developed also in veterinary 
medicine giving several advantages. The primary advantage of 
aCGH over fluorescence in situ hybridization is the array’s ability 
to detect DNA copy changes at multiple loci in a genome within a 
single experiment, including deletions, duplications, or amplifica-
tions. The aCGH method uses slides arrayed with small segments 
of DNA as target for analysis. Instead of using metaphase chro-
mosomes, the array is created by the deposit and immobilization 
of small amounts of DNA, called probes, on a solid support. Two 
studies using oligonucleotide aCGH have been performed in 
canine lymphomas, which result in a gross overview of chromo-
somal imbalance patterns in this tumor (23, 24).
To elucidate copy number variations (CNVs) in cDLBCL, we 
analyzed and compared by aCGH technique, a set of 12 dogs with 
naive DLBCL and treated with similar protocols (17). Relative skin 
punch biopsies were used as DNA reference. The total pattern of 
genomic aberrations consisted of 90 different genomic imbalances 
(mean per tumor, 17). The first aim of the study was to identify 
genomic regions or even CNVs associated with the clinical course 
of the disease. Interestingly, a gain of chr13 was significantly 
more frequent in dogs that presented a complete response after 
the end of treatment compared with dogs that relapsed during 
treatment and in dogs initially diagnosed with stage III and IV 
disease. On the contrary, the gain of the entire chr31 was more 
frequent in dogs with more severe prognosis. Furthermore, since 
chemotherapy is known to be a possible accelerator of clonal evo-
lution, and different patterns of repopulation post therapy have 
been identified in human cancers, going from stable equilibrium 
of subpopulations to alternated dominance between subclones 
over time, we compared ACGH profiles in a subset of dogs that 
relapsed during their lifetime. Interestingly, these dogs showed 
a lower number of genomic imbalances (mean per tumor, 10; 
range, 7–14), equally distributed in gains and losses. In all cases, 
at least one common genomic abnormality was found both in 
the primary DLBCL and relative relapse, confirming the clonal 
relationship between matched tumors (24).
Unfortunately, no works have been performed until now 
integrating GEP and copy number data sets in canine cancer. 
Combining analysis of DNA copy number and gene expression 
microarrays of the same tumor samples has revealed, in human 
tumors, variable direct effect of allelic imbalance on gene expres-
sion. Acquisition of both gene copy number and expression data 
for the same set of samples presents an opportunity to ask how 
gene copy number influences mRNA levels. Significant data are 
expected in the future to corroborate and to combine results that 
have been published so far in canine lymphoma.
Alterations in DnA Methylation in DLBCL
A last topic in canine lymphoma research is related to a promis-
ing concept that has been recently developed in different human 
lymphoproliferative diseases where aberrant DNA methylation 
has been demonstrated to play a key role in hematopoietic tumor 
development, to contribute to disease phenotype, and to be therapy 
related predicting patient survival. Furthermore, just recently, DNA 
methylation and expression signatures have improved the classifi-
cation of human DLBCLs (25). The method of bisulfite conversion 
of DNA is the most efficient to study methylation and is based on 
the selective chemical conversion of all the unmethylated cytosines 
into uracil by treatment with sodium bisulfite, which is then ampli-
fied as thymine during PCR. In contrast, the methylated cytosines 
are not converted, such that, in the final sequencing result, the 
5-methylcytosine will be still detected as cytosine. Following these 
steps, various methods have been determined to quantify DNA 
methylation such as PCR, gel electrophoresis, southern blotting, 
mass spectrometry, and pyrosequencing and applied for specific 
loci or low throughput methylation analysis (26).
In the canine species, the effects of methylation have been 
scarcely investigated, especially in cancer. Few studies are reported 
that investigate perturbations of DNA methylation at single gene 
level, such as DLC1, ABCB1, and FHIT (27–29). DAPK, a suppres-
sor of the cellular transformation at early stages of tumor develop-
ment was found to be hypermethylated with high frequency in 
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canine nodal high-grade B-cell lymphomas (30). DAPK acts as a 
tumor suppressor by sensitizing cells to many apoptotic signals, 
and the promoter methylation may influence the expression of this 
gene. In a different study, p16 hypermethylation and consequent 
silencing was demonstrated in few lymphoma cell lines by bisulfite 
sequencing method and by the indirect effect of a specific meth-
ylation inhibitor (31). Only one study was performed in canine 
DLBCL, and the bisulfite conversion followed by 454 amplicon 
sequencing approach was used for the first time in veterinary 
medicine. This approach appears to be the most innovative and, in 
this study, provided an accurate quantification of TFPI-2 methyla-
tion levels with a single base resolution, allowing the identifica-
tion of CpG sites aberrantly methylated in canine DLBCLs. The 
selection of the gene was made on the previous identification 
of a significant downregulation of TFPI-2 mRNA levels in dogs 
affected by DLBCL compared with healthy lymph node controls 
(32). In future, a genome-wide approach to investigate global 
perturbations of methylation in canine lymphomas will become 
worthwhile to test the hypothesis that hypomethylation is able 
to increase genomic instability and to activate proto-oncogenes, 
whereas hypermethylation contributes to tumorigenesis by silenc-
ing tumor suppressor genes. The most promising methodologies 
are now based on high-throughput sequencing.
COnCLUSiOn
In conclusion, most of the data reported in this review indicate 
the extreme heterogeneity of canine DLBCL and the lack of 
definitive diagnostic and therapeutic protocols. Several different 
approaches are currently in use, but are not comparable. This 
deficit affects both clinicopathological and experimental studies, 
including clinical trials. In this contest, the biological data that 
have been published in canine DLBCL are probably unique in 
veterinary oncology and are one of the most significative exam-
ples of the extreme biological diversity within a single tumor 
histotype. Canine DLBCL cannot be longer regarded as a single 
disease, because the biological behavior has been demonstrated 
to be dependent on its activated B-cell origin or not, associa-
tion with mitotic index, blood and BM tumor infiltration, and 
specific genomic aberrations. In the future, therapeutic decisions 
will increasingly be correlated to the analysis of these data, and 
their significance need to be further validated in a larger cohort 
of dogs.
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